7.62
-0.25(-3.18%)
Currency In USD
| Previous Close | 7.87 |
| Open | 7.89 |
| Day High | 8.17 |
| Day Low | 7.57 |
| 52-Week High | 10.43 |
| 52-Week Low | 1.73 |
| Volume | 1.28M |
| Average Volume | 1.54M |
| Market Cap | 233.74M |
| PE | -4.28 |
| EPS | -1.78 |
| Moving Average 50 Days | 4.7 |
| Moving Average 200 Days | 4.41 |
| Change | -0.25 |
If you invested $1000 in Sagimet Biosciences Inc. (SGMT) since IPO date, it would be worth $477.74 as of July 01, 2025 at a share price of $7.62. Whereas If you bought $1000 worth of Sagimet Biosciences Inc. (SGMT) shares 1 year ago, it would be worth $2,411.39 as of July 01, 2025 at a share price of $7.62.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Sagimet Biosciences to Host Virtual KOL Event, “A New Mechanism of Action in Treating Acne: Update on Positive Phase 3 Denifanstat Trial for the Treatment of Moderate to Severe Acne” on June 16, 2025
GlobeNewswire Inc.
Jun 09, 2025 11:00 AM GMT
SAN MATEO, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced it will
Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat for the Treatment of Moderate-to-Severe Acne from Partner Ascletis
GlobeNewswire Inc.
Jun 04, 2025 9:00 AM GMT
Denifanstat met all primary and secondary endpoints versus placebo Denifanstat was well tolerated Oral FASN inhibitors offer a novel mechanism of action for the potential treatment of moderate to severe acne Sagimet initiated first-in-human Phase 1 c
Sagimet Biosciences to Host Virtual KOL Event, “Evaluating the Synergistic Potential of a Combination of Denifanstat and Resmetirom for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)” on May 29, 2025
GlobeNewswire Inc.
May 22, 2025 12:00 PM GMT
SAN MATEO, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced it will h